Jacobs Levy Equity Management
NMRA icon

Jacobs Levy Equity Management’s Neumora Therapeutics NMRA Stock Holding History

Jacobs Levy Equity Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$689K Buy
405,324
+131,454
+48% +$250K ﹤0.01% 778
2026
Q1 		$534K Sell
273,870
-200,610
-42% -$520K ﹤0.01% 818
2025
Q4 		$849K Sell
474,480
-356,338
-43% -$780K ﹤0.01% 713
2025
Q3 		$1.51M Buy
+830,818
New +$1.34M 0.01% 642

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Levy Equity Management's NMRA Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Neumora Therapeutics (NMRA) stake by 48% in Q2 2026, buying an estimated $250K and bringing the position to 405,324 shares worth $689K. The position accounts for ﹤0.01% of the portfolio, ranked #778.

Jacobs Levy Equity Management first reported a position in NMRA in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.51M in Q3 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Jacobs Levy Equity Management held 405,324 shares of Neumora Therapeutics worth $689K as of Q2 2026.
  • Jacobs Levy Equity Management bought 131,454 Neumora Therapeutics shares in Q2 2026, an estimated $250K.
  • Neumora Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #778 holding.
  • Jacobs Levy Equity Management first reported a position in Neumora Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Jacobs Levy Equity Management's Neumora Therapeutics position peaked at $1.51M in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.